Uniretic

Hypertensive disease

Treatment

1 FDA approval

20 Active Studies for Uniretic

What is Uniretic

Moexipril

The Generic name of this drug

Treatment Summary

Hydrochlorothiazide is a drug used to treat high blood pressure and fluid retention. It is the most widely prescribed thiazide diuretic and is often used in combination with other medications such as angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. Hydrochlorothiazide was approved by the FDA in 1959 and is still widely used today, although it has been decreasing in popularity due to the emergence of newer medications.

Univasc

is the brand name

Uniretic Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Univasc

Moexipril

1995

42

Approved as Treatment by the FDA

Moexipril, commonly known as Univasc, is approved by the FDA for 1 uses like Hypertensive disease .

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Hydrochlorothiazide

Effectiveness

How Uniretic Affects Patients

Hydrochlorothiazide works by stopping the kidneys from taking in too much water and salt. The amount of this drug taken can vary depending on the person and usually ranges from 25-100mg. Those with reduced kidney or liver function should be careful when taking this medication.

How Uniretic works in the body

Hydrochlorothiazide works by blocking sodium from being reabsorbed into cells in the distal convoluted tubule of the kidneys. Normally, sodium is reabsorbed from the tubule and deposited into the basolateral interstitium, which creates a concentration gradient that draws water back into the cells. Hydrochlorothiazide prevents this process by blocking the sodium-chloride symporter, which decreases the concentration gradient and reduces the reabsorption of water.

When to interrupt dosage

The amount of Uniretic is contingent on the identified condition, including Antepartum magnesium sulfate protection, blood pressure inadequately managed with monotherapy and antihypertensives. The dosage fluctuates as per the mode of delivery (e.g. Tablet, coated - Oral or Oral) delineated in the table beneath.

Condition

Dosage

Administration

Hypertensive disease

, 7.5 mg, 15.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated

Warnings

Uniretic has two counter-indications, and so should not be taken when present with any of the conditions listed in the following table.

Uniretic Contraindications

Condition

Risk Level

Notes

Angioedema

Do Not Combine

Type 2 Diabetes

Do Not Combine

Pulse Frequency

Do Not Combine

Anuria

Do Not Combine

There are 20 known major drug interactions with Uniretic.

Common Uniretic Drug Interactions

Drug Name

Risk Level

Description

Amifostine

Major

Moexipril may increase the hypotensive activities of Amifostine.

Azathioprine

Major

The risk or severity of myelosuppression, anemia, and severe leukopenia can be increased when Moexipril is combined with Azathioprine.

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Moexipril is combined with Hydroxyzine.

Lithium carbonate

Major

The serum concentration of Lithium carbonate can be increased when it is combined with Moexipril.

Lithium citrate

Major

The serum concentration of Lithium citrate can be increased when it is combined with Moexipril.

Uniretic Toxicity & Overdose Risk

The lowest toxic dose of hydrochlorothiazide in mice and rats is greater than 10g/kg. Those who overdose may experience low potassium, chloride, and sodium levels. Treatment for an overdose should include fluids, electrolytes, and supportive care such as vasopressors to regulate blood pressure and oxygen for respiratory issues.

image of a doctor in a lab doing drug, clinical research

Uniretic Novel Uses: Which Conditions Have a Clinical Trial Featuring Uniretic?

Condition

Clinical Trials

Trial Phases

Hypertensive disease

37 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Uniretic Reviews: What are patients saying about Uniretic?

5

Patient Review

11/4/2009

Uniretic for High Blood Pressure

4.3

Patient Review

3/11/2009

Uniretic for High Blood Pressure

4

Patient Review

12/1/2010

Uniretic for High Blood Pressure

I sometimes feel nauseous after taking this medication.

3.7

Patient Review

3/13/2009

Uniretic for High Blood Pressure

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about uniretic

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Univasc used for?

"Univasc is a prescription medication used to address the symptoms of hypertension, and can be used either alone or in conjunction with other drugs. It belongs to a class of drugs referred to as ACE inhibitors."

Answered by AI

What does HCTZ stand for?

"Hydrochlorothiazide is a diuretic that helps reduce water retention by increasing urine output. It is only available with a doctor's prescription."

Answered by AI

Is Moexipril a diuretic?

"Before taking moexipril, it is important to tell your doctor about all other medications you are taking, including over the counter drugs and supplements. You should also share any other medical conditions you have. Diuretic therapy should be discontinued, if possible, 2 to 3 days before starting moexipril. If blood pressure remains uncontrolled with this drug alone, diuretic therapy may be restarted."

Answered by AI

When is the best time to take Moexipril?

"Store the medicine in a closed container at room temperature

Dosing. The dose of this medicine will differ among patients. ... , Missed Dose. If you miss a dose of this medicine, try to take it as soon as you remember. ... , Storage. Keep the medicine in a closed container at room temperature"

Answered by AI

Clinical Trials for Uniretic

Image of UCSF Medical Center at Parnassus in San Francisco, United States.

Blood Pressure Monitoring for Atrial Fibrillation

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if screening for atrial fibrillation (AFib), a common irregular heart rhythm, through daily home blood pressure monitoring will decrease the time to atrial fibrillation diagnosis in older adults with hypertension. The main question it aims to answer is: \-- Does introducing screening for AFib using a blood pressure monitor with AFib detection technology decrease time to AFib diagnosis in patients with high blood pressure, compared to usual care using a conventional home blood pressure monitor with no AFib detection? Participants will participate in two phases of the study: (1) clinical trial and (2) the registry. During the 6-month clinical trial period, participants will be asked to: * Take blood pressure measurements twice daily * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take blood pressure measurements twice daily * Answer monthly mobile app-based surveys Researchers will compare standard blood pressure measurements and AFib screening blood pressure measurements to see if there is a difference in the time to AFib diagnosis and other cardiovascular events. Participants will participate in two phases of the study: (1) trial and (2) the registry. During the 6-month trial period, participants will be asked to: * Take daily blood pressure measurements * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take daily blood pressure measurements * Answer monthly mobile app-based surveys

Waitlist Available
Has No Placebo

UCSF Medical Center at Parnassus

Gregory M Marcus, MD, MAS

Omron Healthcare Co., Ltd.

Image of Hāmākua-Kohala Health Center in Honokaa, United States.

Produce Prescription for High Blood Pressure

18+
All Sexes
Honokaa, HI

This multi-site randomized controlled trial uses a community-based approach to evaluate a Food as Medicine program for Native Hawaiian and Pacific Islander (NHPI) adults in Hawaii who have high blood pressure and difficulty affording healthy food. The study has two main goals: (1) to implement a produce prescription program and see if adding personal support from Community Health Workers (CHW) improves blood pressure among other health outcomes, and (2) to determine the program's cost-effectiveness. The study will take place across three Federally Qualified Health Centers in Hawaii. Produce prescription program participants at each site will receive $100 per month, either in the form of produce boxes or monthly vouchers to purchase fruits and vegetables, for 12 months (totaling $1200). In past studies, personal challenges (e.g., lack of transportation, lack of cooking skills) have made it difficult for participants to use the vouchers and/or the purchased produce. In other food as medicine interventions, participants have similarly faced various personal, social, and environmental barriers that limit the program's efficacy. To help participants navigate through these challenges, the investigators want to test adding 1-on-1 support from a CHW throughout the program. Other studies have found that health interventions delivered by CHWs have been effective in reducing blood pressure, blood glucose and weight, especially among vulnerable populations, such as NHPIs and those with food insecurity. The CHWs in this study will receive a training using a curriculum tailored specifically to their community and that is in alignment with the Pilinahā: The Four Connections Framework, which focuses on key connections that Indigenous people seek to attain health and can be employed to overcome health disparities. To test the effectiveness of the added CHW support, there will be two groups of participants: Group 1 (Intervention) will receive the monthly produce prescription ($100 vouchers or produce box) plus meet with a CHW every two months for support with program challenges. Group 2 (Control) will receive the same monthly produce prescription, but will not have meetings with a CHW. The investigators want to see if the added support from CHWs leads to better blood pressure results, among other health outcomes. Upon providing informed consent and enrolling into the program, produce prescription program participants will: * Attend 5 study visits over the one year program. These happen at the start, and then at 3, 6, 9, and 12 months. * Complete health checks at the first visit. This includes getting a home blood pressure monitor and learning about heart health and nutrition. Staff will measure height, weight, waist size, and blood pressure. * Answer surveys about their demographic background, health habits, diet, and culture. * Receive $100 in vouchers every month for 12 months to redeem for fruits and vegetables at a local retailer. * Group 1 will additionally meet with a CHW every two months for 1-on-1 support with any challenges related to the program. * Group 2 will receive monthly reminders to use their vouchers but no CHW meetings. After the program ends, researchers will analyze the financial value of the intervention. This involves calculating the total cost to run the program (including vouchers, CHW training and salaries, and administrative costs) and comparing it to potential savings in healthcare costs. By looking at improvements in blood pressure, researchers can estimate how many heart-related health problems were prevented and how much money was saved on medical care.

Waitlist Available
Has No Placebo

Hāmākua-Kohala Health Center (+2 Sites)

Have you considered Uniretic clinical trials?

We made a collection of clinical trials featuring Uniretic, we think they might fit your search criteria.
Go to Trials
Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are conducting a Type 3 hybrid effectiveness-implementation trial to evaluate the implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 400 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The aims of this study are threefold: 1. To evaluate the implementation of the PPP across multiple community sites using a Type 3 hybrid effectiveness-implementation design guided by established frameworks such as RE-AIM and PRISM. 2. To examine participant-level outcomes associated with PPP implementation, including changes in cardiometabolic risk factors, health behaviors, and SDOH factors from baseline to 3 and 9-month follow-up. 3. To evaluate the cost and cost-effectiveness of implementing the PPP across community settings.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Have you considered Uniretic clinical trials?

We made a collection of clinical trials featuring Uniretic, we think they might fit your search criteria.
Go to Trials
Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Recruiting
Has No Placebo

U Health (+5 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Waitlist Available
Has No Placebo

University of Alabama at Birmingham

Pankaj Arora, MD, FAHA

Have you considered Uniretic clinical trials?

We made a collection of clinical trials featuring Uniretic, we think they might fit your search criteria.
Go to Trials